• Explore /
  • Poster
  • / Trial in progress: Phase 1b/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus mFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102).

Trial in progress: Phase 1b/3 study of bemarituzumab + mFOLFOX6 + nivolumab versus mFOLFOX6 + nivolumab in previously untreated advanced gastric and gastroesophageal junction (GEJ) cancer with FGFR2b overexpression (FORTITUDE-102).

Abstract Poster

Authors

null

Zev A. Wainberg

UCLA School of Medicine, Los Angeles, CA

Zev A. Wainberg , Eric Van Cutsem , Markus H. Moehler , Yoon-Koo Kang , Priscilla Yen , Elizabeth Finger , Alissa Keegan , Kohei Shitara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT05111626

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS4165)

DOI

10.1200/JCO.2022.40.16_suppl.TPS4165

Abstract #

TPS4165

Poster Bd #

148a

Abstract Disclosures

Similar Posters

First Author: Elizabeth Catherine Smyth

Poster

2019 Gastrointestinal Cancers Symposium

Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).

Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).

First Author: Mohamedtaki Abdulaziz Tejani

First Author: Kohei Shitara

First Author: Samuel J Klempner